FG 001
Alternative Names: FG-001; FG001 sodium; ICG-Glu-Glu-AE105Latest Information Update: 05 Feb 2026
At a glance
- Originator FluoGuide
- Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Yes - Glioma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Glioblastoma; Glioma; Head and neck cancer; Meningioma; Non-small cell lung cancer; Squamous cell cancer
- No development reported Pancreatic cancer
Most Recent Events
- 21 Jan 2026 FluoGuide files an IND application with the US FDA in US to initiate first phase II registration trial for Glioma
- 21 Jan 2026 FluoGuide plans a Phase II registration trial for Glioma in the US in Q2 2026
- 19 Dec 2025 FluoGuide announces intention to file IND application with the US FDA in USA for Glioma in mid-January 2026